Therapeutic Asset Ratings

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Inno-206 Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P4	BBB (74)
Inno-206 Ovarian Neoplasm	GlaxoSmithKline	P4	BBB (74)
Inno-206 Peripheral T-Cell Lymphoma, Not Otherwise Specified	BeBetter Med Inc	P4	BBB (74)
Iparomlimab HCC - Hepatocellular Carcinoma	Hebei Medical University Fourth Hospital	P4	BBB (74)
Irinotecan Recurrent Ovarian Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P4	BBB (74)
Keppra Epilepsy	Beijing Tiantan Hospital	P4	BBB (74)
Lacosamide Epilepsy	Second Affiliated Hospital of Guangzhou Medical University	P4	BBB (74)
LACTULOSE Hepatic Encephalopathy	General Hospital of Shenyang Military Region	P4	BBB (74)
Lamivudine HIV Infectious Disease	José Antonio Mata Marín	P4	BBB (74)
LAMOTRIGINE Epilepsy	Assiut University	P4	BBB (74)
Letrozole Invasive Breast Carcinoma	Emory University	P4	BBB (74)
Letrozole Type 1 Diabetes	Heba M. Ismail	P4	BBB (74)
LEUPROLIDE Prostate Carcinoma	Mayo Clinic	P4	BBB (74)
LITHIUM, ELEMENTAL Bipolar Disorder	University of Aarhus	P4	BBB (74)
LITHIUM, ELEMENTAL Depressive Disorder	Rakitzi, Stavroula	P4	BBB (74)
MELATONIN Traumatic Brain Injury	Children's National Research Institute	P4	BBB (74)
Metformin Diastolic Heart Failure	Sara ElAdawy	P4	BBB (74)
Metformin Female Infertility	Peking University Third Hospital	P4	BBB (74)
Metformin Metabolic Syndrome	Islamabad Medical and Dental College	P4	BBB (74)
Metformin Metabolic Dysfunction-Associated Steatotic Liver Disease	Xiqiao Zhou	P4	BBB (74)
Metformin Polycystic Ovary Syndrome	Beni-Suef University	P4	BBB (74)
METHOTREXATE B-Cell Non-Hodgkin Lymphoma	Children's Cancer Group, China	P4	BBB (74)
N-Acetyl-L-Cysteine Idiopathic Pulmonary Fibrosis	Endeavor Biomedicines, Inc.	P4	BBB (74)
Naltrexone Rheumatoid Arthritis	Truway Health, Inc.	P4	BBB (74)
Namenda Alzheimer Disease	Carnot Laboratories	P4	BBB (74)

Showing 526 to 550 of 61,847 assets

PreviousPage 22 of 2474Next